Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...
Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday. Shares of Exact ...
Research on the solar system is becoming more and more precise. The University of Warwick and NASA, after many years of study ...
Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...
Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a ...
Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.
Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.